Nutriband Inc. Advances Aversa Fentanyl to Commercial Manufacturing Scale with Kindeva

Nutriband Inc. (NASDAQ: NTRB), in collaboration with Kindeva, a global contract development and manufacturing organization (CDMO), has achieved a significant milestone by scaling up the commercial manufacturing process for Aversa Fentanyl. This product combines Nutriband's AVERSA abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch, produced at Kindeva's U.S.-based transdermal facility. The advancement represents a critical step in the development of the world's first abuse-deterrent opioid patch, aiming to mitigate the risks of abuse, misuse, and accidental exposure associated with opioids.

The next phases involve producing clinical supplies and submitting an Investigational New Drug application to initiate a human abuse liability study. Nutriband projects that Aversa Fentanyl could achieve peak U.S. sales between $80 million and $200 million, with potential for significant global market penetration supported by its extensive international patent portfolio. This development is pivotal in the fight against the opioid crisis, offering a safer alternative for pain management while addressing the critical issue of drug abuse.

The collaboration between Nutriband and Kindeva underscores the importance of innovation in pharmaceutical development, particularly in creating solutions that enhance patient safety and public health. The successful scale-up of Aversa Fentanyl's manufacturing process not only highlights the potential for substantial commercial success but also the broader implications for reducing opioid abuse and its devastating impact on communities worldwide.